Form D · Pharmaceuticals
Enalare Therapeutics Inc.
Princeton, NJ · CIK 0001835701
Offering snapshot reported Aug 15, 2022 · SEC filing
- Reported sold
- $12.5M Offering amount: $55M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 8, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 15, 2022 | Initial | $12,500,000 | No comparison | 1 | SEC filing |
| Feb 7, 2022 | Initial | $1,025,875 | No comparison | 12 | SEC filing |
| Dec 21, 2020 | Amendment | Yet to sell | No comparison | 0 | SEC filing |
| Dec 11, 2020 | Initial | Yet to sell | No comparison | 0 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-456016
Source: Form D, filed Aug 15, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Mark Coleman | Director |
| Herman Cukier | Director, Executive |
| Daniel Motto | Executive |
| Joseph Pergolizzi | Director, Executive |
| Joseph Petko | Director |
| Gino Santini | Director |
| Robert Yedid | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
161 Hodge Road
Princeton, NJ, 08540
Princeton, NJ, 08540